New study tracks safety of clotting drug for hemophilia patients in india

NCT ID NCT07446010

Not yet recruiting Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the safety and effectiveness of Octocog alfa, a lab-made clotting factor, when used to treat sudden bleeding episodes in adults with severe hemophilia A. About 33 people in India who have used factor VIII before will take part. Researchers will track side effects and how well the drug controls bleeds in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A severe hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • All India Institute Of Medical Sciences

    New Delhi, India

  • Christian Medical College & Hospital

    Ludhiana, India

  • Department of Medicine Assam Medical College & Hospital

    Dibrugarh, India

  • Government of Medical College Kozhikode

    Kozhikode, India

  • Sahyadri Super Speciality Hospital

    Pune, India

  • Sanjay Gandhi Post Graduate Institute & Medical Sciences

    Lucknow, India